In a recent interview at the annual RSNA conference in Chicago, Richard Heller, MD discussed the impact of reduced reimbursement rates in radiology, the projected CMS conversion factor for 2024, the severity of payment cuts in interventional radiology and the importance of radiologist advocacy.
Despite significant demand for radiologist services, Richard Heller, MD, noted that declining radiology reimbursement amid a backdrop of significant workforce shortages have created a “perfect storm” of stress for radiologists.
“We’ve got this demand coupled with a capacity limitation but at the same time we’re facing that, we’re also facing downward pressure on our reimbursement both from public payers like Medicare and commercial health-care payers,” explained Dr. Heller, the associate chief medical officer for Health Policy and Communications with Radiology Partners, during a recent interview at the annual RSNA conference in Chicago. “We’re doing all of this at a time of inflation. … At the same time you’re feeling overwhelmed with the (imaging) volume and demand, you’re getting paid less for that work.”
Based on 2024 projections of the conversion factor set by the Centers for Medicare and Medicaid Services (CMS) for Medicare reimbursement, declining radiologist reimbursement may become significantly worse.
“CMS has finalized a conversion factor for 2024 that would be lower than the conversion factor they used in 1994,” emphasized Dr. Heller. “To be clear, I’m not talking about inflation. The actual dollar value that CMS intends to pay doctors with in 2024 is lower than it was 30 years earlier in 1994.”
(Editor’s note: For related content, see “Stabilizing Medicare Reimbursement: a Plan for Action,” “Outpatient Reimbursement to Increase 65 Percent for EchoGo Heart Failure Platform in 2024” and “CMS Issues New Reimbursement Code for PSMA PET Agent POSLUMA.”)
Dr. Heller added that interventional radiology is projected to take the biggest CMS reimbursement cuts of any specialty in 2024.
“You’re disincentivizing investments in and disadvantaging a specialty, which I think we would all agree is minimally invasive and cost-effective,” maintained Dr. Heller. “It’s counterintuitive to disadvantage a specialty like interventional radiology, which actually improves the value of health care delivery.”
For more insights from Dr. Heller, watch the video below.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
RSNA 2020: Addressing Healthcare Disparities and Access to Care
December 4th 2020Rich Heller, M.D., with Radiology Partners, and Lucy Spalluto, M.D., with Vanderbilt University School of Medicine, discuss the highlights of their RSNA 2020 session on health disparities, focusing on the underlying factors and challenges radiologists face to providing greater access to care.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
SNMMI: Can Multimodal Monitoring Bolster Outcomes with Pluvicto in Treating mCRPC?
June 22nd 2025Multimodal treatment monitoring, including SPECT/CT exams 24 hours after treatment with Lu-177 PSMA-617, may have facilitated significantly shorter therapy durations and reduced side effects in patients with mCRPC, according to a two-year study presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.